Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 779-781

  Dorum A ^a   Hovig, E ^a   Trope C ^a   Inganas, M ^b   Moller P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b GE Healthcare Bio Sciences AB   (Sweden)

Author keywords

BRCA1; Founder mutations; Hereditary breast ovarian cancer; Prognostic factors

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NORWAY; ONCOGENE; ONSET AGE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; FEMALE; FOUNDER EFFECT; GENES, BRCA1; HUMANS; MIDDLE AGED; MUTATION; NORWAY; OVARIAN NEOPLASMS; PEDIGREE; PREVALENCE; PROGNOSIS;

EID: 0033031573     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00050-7     Document Type: Article

References (13)

1. King M-C., Szabo C.I. Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet. 60:1997;1013-1020.
2. Engeland A., Haldorsen T., Tretli S., et al. Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS. 101:(Suppl. 38):1993;61-63.
3. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. New Engl. J. Med. 339:1998;424-428.
4. Dørum A., Kristensen G.B., Abeler V.M., Tropeé C.G., Møller P. Early detection of familial ovarian cancer. Eur. J. Cancer. 32A:1996;1645-1651.
5. Jacobs I., Oram D. Screening for ovarian cancer. Biomed. Pharmacother. 42:1988;589-596.
6. Stratton J.F., Gayther S.A., Russel P., et al. Contribution of BRCA1 mutations to ovarian cancer. New Engl. J. Med. 336:1997;1125-1130.
7. Struewing J.P., Abeliovich D., Peretz T., et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genetics. 11:1995;198-200.
8. Johannsson O.T., Ostermeyer E., Håkansson S., et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am. J. Hum. Genet. 58:1996;441-450.
9. Andersen T.I., Borresen A.L., Moller P. A common BRCA1 mutation in Norwegian breast and ovarian families. Am. J. Hum. Genet. 59:(2):1996;486-487.
10. Dørum A., Møller P., Kamsteeg E.J., et al. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Eur. J. Cancer. 33:1997;2390-2392.
11. Peelen T., van Vliet M., Petrij-Bosch A., et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am. J. Hum. Genet. 60:1997;1041-1049.
12. Arason A., Jonasdottir A., Barkardottir R.B., et al. A population study of mutations and LOH at breast cancer gene loci in tumour from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J. Med. Genet. 35:1998;446-449.
13. Bjørge T., Engeland A., Sundfør K., Trope C. Prognosis of 2800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet. Gynecol. Scand. 77:1998;777-781.